JOHN KIRKWOOD to Immunologic Factors
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Immunologic Factors.
Connection Strength
0.937
-
Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol. 2008 Jan; 5(1):2-3.
Score: 0.222
-
Cancer immunotherapy: the interferon-alpha experience. Semin Oncol. 2002 Jun; 29(3 Suppl 7):18-26.
Score: 0.152
-
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade. JAMA Oncol. 2019 07 01; 5(7):942-943.
Score: 0.124
-
Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients. J Immunother. 1997 Sep; 20(5):387-98.
Score: 0.110
-
Adjuvant interferon-a for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017 09; 82:171-183.
Score: 0.109
-
Immune checkpoint blockade and interferon-a in melanoma. Semin Oncol. 2015 Jun; 42(3):436-47.
Score: 0.092
-
STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy. J Invest Dermatol. 2008 Aug; 128(8):1997-2002.
Score: 0.057
-
Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res. 2007 Jun; 17(3):193-200.
Score: 0.054
-
Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res. 2010 Oct; 23(5):e1-7.
Score: 0.017